FDA Grants Accelerated Approval to Rybrevant Faspro for Head and Neck Cancer
The U.S. Food and Drug Administration has granted accelerated approval to Rybrevant Faspro, combining amivantamab and hyaluronidase-lpuj, for treating adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed following platinum-based chemotherapy and immunotherapy.
The approval was based on clinical trial results showing an overall response rate of 42 percent among patients, with a significant proportion experiencing durable responses lasting six months or longer. However, the indication explicitly excludes patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.
The therapy carries important warnings and precautions regarding hypersensitivity and administration-related reactions, interstitial lung disease, pneumonitis, dermatologic adverse reactions, ocular toxicity, and potential harm to unborn babies. Because this approval was granted under the Accelerated Approval Program based on surrogate endpoints, continued approval depends on the verification of clinical benefit in confirmatory trials.
Key points
- Rybrevant Faspro received accelerated approval for recurrent or metastatic head and neck squamous cell carcinoma.
- Patients must have experienced disease progression on or after platinum-based chemotherapy and immunotherapy.
- The drug is not indicated for patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.
- Clinical trial results demonstrated an overall response rate of 42 percent.
- Prescribing information includes warnings for hypersensitivity, interstitial lung disease, dermatologic reactions, and ocular toxicity.
What it means for you
This new approval offers a treatment option for patients with advanced head and neck squamous cell carcinoma who have progressed on prior therapies. Clinicians should review the specific trial criteria, patient exclusion for HPV-associated disease, and safety warnings including interstitial lung disease and hypersensitivity. Because this is an FDA announcement, clinicians and pharmacists in Pakistan should check with DRAP regarding the local availability and registration status of this product.
FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.